Evidence map›Paper›PMID 40884399›Full record

ArticleNucleic acids research2025

HIV-2 evades restriction by ZAP through adaptations in the U3 LTR region despite increased CpG levels.

Dorota Kmiec, Rayhane Nchioua, Alexander Gabel, Asimenia Vlachou, Sabina Ganskih, Sümeyye Erdemci-Evin, Stacey A Lapp, Diane G Carnathan, Steven E Bosinger, Ben Berkhout and 3 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dorota KmiecInstitute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.ORCID 0000-0001-7302-6015
Rayhane NchiouaInstitute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.
Alexander GabelHelmholtz Institute for RNA-Based Infection Research, Würzburg 97080, Germany.
Asimenia VlachouInstitute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.
Sabina GanskihHelmholtz Institute for RNA-Based Infection Research, Würzburg 97080, Germany.
Sümeyye Erdemci-EvinInstitute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.
Stacey A LappDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University Atlanta, GA 30322, United States.
Diane G CarnathanDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University Atlanta, GA 30322, United States.
Steven E BosingerDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University Atlanta, GA 30322, United States.
Ben BerkhoutAmsterdam University Medical Center, University of Amsterdam, Medical Microbiology and Infection Prevention, 1105AZ, Amsterdam, Netherlands.
Atze T DasAmsterdam University Medical Center, University of Amsterdam, Medical Microbiology and Infection Prevention, 1105AZ, Amsterdam, Netherlands.
Mathias MunschauerHelmholtz Institute for RNA-Based Infection Research, Würzburg 97080, Germany.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.ORCID 0000-0002-7052-2360

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Baden-Württemberg foundationElse-Krönung Fresenius Stiftun 2022_EKEA.47Emory National Primate Research CenterEuropean Research Council 101040914European Research Council ERC-StG COVIDecodeEuropean Union's Horizon 2020Helmholtz Young Investigator Group Program VH-NG-128Marie Sklodowska-Curie 101062524National Institute of Allergy and Infectious DiseasesNIH HHS P51 OD011132NIH HHS R37 AI66998Ulm University Medical Center
6 · The paper itself

Abstract

Simian immunodeficiency viruses infecting sooty mangabeys (SIVsmm) gave rise to nine groups of human immunodeficiency virus type 2 (HIV-2). Two of these (A and B) spread substantially with an estimated 1-2 million individuals affected. The evolutionary adaptations that facilitated HIV-2's spread in humans are still poorly understood. Here, we report that diverse SIVsmm strains efficiently infect primary human T cells. However, they are more sensitive to interferon than HIV-2, indicating that interferon-stimulated genes (ISGs) pose a barrier to the successful spread of SIVsmm in humans. One of the best-known antiviral ISGs is the zinc finger antiviral protein (ZAP), which targets CpG dinucleotides in RNA. To evade ZAP-mediated restriction, many viruses, including HIV-1, suppress their CpG content. Unexpectedly, we found that HIV-2 is more resistant to ZAP restriction than HIV-1 and SIVsmm despite having 33% more CpGs. Identification of ZAP-binding sites using RNA enhanced crosslinking immunoprecipitation and analyses of chimeric HIV-2/SIVsmm viruses revealed that the determinants of ZAP resistance map to the nef/U3 region and promote HIV-2 replication in primary human T cells. Our results indicate that HIV-2 evolved a CpG-independent ZAP resistance mechanism which might have been facilitated by relaxed functional constraints acting on Nef in the human host.

Indexed as

CpG IslandsHIV-2HIV Long Terminal RepeatRNA-Binding ProteinsAnimalsBinding SitesHIV-1HumansSimian Immunodeficiency VirusT-LymphocytesVirus ReplicationRNA-Binding ProteinsZC3HAV1 protein, human

Identifiers

PMID40884399
PMCPMC12397911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.